VIA
BCAX

Virtus Investment Advisers’s Bicara Therapeutics BCAX Stock Holding History

Virtus Investment Advisers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
15,086
+331
+2% +$7.39K 0.1% 224
2026
Q1 		$293K Buy
14,755
+360
+3% +$6.2K 0.08% 282
2025
Q4 		$242K Buy
14,395
+4,560
+46% +$77.9K 0.07% 343
2025
Q3 		$155K Buy
9,835
+1,708
+21% +$19.1K 0.04% 370
2025
Q2 		$75.5K Sell
8,127
-970
-11% -$11.6K 0.03% 432
2025
Q1 		$119K Buy
+9,097
New +$121K 0.03% 395

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's BCAX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Bicara Therapeutics (BCAX) stake by 2.2% in Q2 2026, buying an estimated $7.39K and bringing the position to 15,086 shares worth $448K. The position accounts for 0.1% of the portfolio, ranked #224.

Virtus Investment Advisers first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Virtus Investment Advisers held 15,086 shares of Bicara Therapeutics worth $448K as of Q2 2026.
  • Virtus Investment Advisers bought 331 Bicara Therapeutics shares in Q2 2026, an estimated $7.39K.
  • Bicara Therapeutics made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #224 holding.
  • Virtus Investment Advisers first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.